Home
About
Overview
Sharing Data
ORCID
Help
History (30)
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
Crohn's disease: step up or top down therapy.
A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis.
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
See All 30 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17.
View in:
PubMed
subject areas
Adalimumab
Adult
Antibodies, Monoclonal, Humanized
Anti-Inflammatory Agents
Crohn Disease
Double-Blind Method
Female
Glucocorticoids
Humans
Male
Middle Aged
Remission Induction
Time Factors
Treatment Outcome
authors with profiles
Stephen B. Hanauer